^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Osteosarcoma
    Regimen:IE (etoposide IV + ifosfamide)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    11/20/2020
    Excerpt:
    Osteosarcoma: Second-line therapy (relapsed/refractory or metastatic disease)…Preferred Regimens…Ifosfamide (high dose) ± etoposide
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Title:

    Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Excerpt:
    Summary of recommendations...Treatment (locoregional and advanced disease)...Second-line ChT for recurrent OS includes ifosfamide or cyclophosphamide, possibly in association with etoposide and/or carboplatin [III, B], and other active drugs including gemcitabine and docetaxel [IV, C], sorafenib [III, B] or regorafenib [II, B].
    DOI:
    10.1093/annonc/mdy310